{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:32:52Z","timestamp":1780353172368,"version":"3.54.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate if the OMERACT PsA MRI Scoring System (PsAMRIS), including a novel total inflammation score, shows sensitivity to change with an agent (abatacept) known to impact clinical outcomes in PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a post hoc analysis of a randomized phase IIb study of abatacept in patients with PsA and inadequate DMARD response. Participants received one of three abatacept dosing regimens [ABA3, ABA10 or ABA30\/10\u2009mg\/kg (30\u2009mg\/kg switched to 10\u2009mg\/kg after two doses)] or placebo until day 169, then ABA10 through day 365. MRIs at baseline and days 85, 169 and 365 were centrally evaluated by two readers blinded to chronological order and treatment arm. Synovitis, osteitis, tenosynovitis, periarticular inflammation, bone erosions, joint space narrowing and bone proliferation were assessed using the PsAMRIS. A novel total inflammation score was tested.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>MRIs for 123 patients were included. On day 169, ABA10 and ABA30\/10 significantly reduced MRI synovitis and tenosynovitis, respectively, vs placebo [differences \u22120.966 (P\u2009=\u20090.039) and \u22121.652 (P\u2009=\u20090.014), respectively]. Synovitis in the placebo group increased non-significantly from baseline to day 169, total inflammation and tenosynovitis decreased non-significantly and all measures improved significantly after a switch to ABA10 [\u22121.019, \u22120.940, \u22122.275 (P\u2009&amp;lt;\u20090.05), respectively, day 365 vs day 169]. Structural outcomes changed minimally across groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Adults with PsA receiving ABA10 and ABA30\/10 demonstrated significant resolution of inflammatory components of disease, confirmed by MRI, with synovitis and tenosynovitis improvements consistent with previously reported clinical responses for these doses. Results indicate that a reduction in OMERACT PsAMRIS inflammation scores may provide proof of tissue-level efficacy in PsA clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov (https:\/\/clinicaltrials.gov), NCT00534313.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac073","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T04:43:15Z","timestamp":1643431395000},"page":"4305-4313","source":"Crossref","is-referenced-by-count":10,"title":["Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-467X","authenticated-orcid":false,"given":"Mikkel","family":"\u00d8stergaard","sequence":"first","affiliation":[{"name":"Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Rigshospitalet , Glostrup"},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bird","sequence":"additional","affiliation":[{"name":"Division of Medicine, University of New South Wales , Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chahin","family":"Pachai","sequence":"additional","affiliation":[{"name":"Translational Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Du","sequence":"additional","affiliation":[{"name":"Translational Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wu","sequence":"additional","affiliation":[{"name":"Translational Bioinformatics, Bristol Myers Squibb , Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Landis","sequence":"additional","affiliation":[{"name":"Translational Bioinformatics, Bristol Myers Squibb , Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fuerst","sequence":"additional","affiliation":[{"name":"Medical and Scientific Affairs, Bioclinica Inc. , Newark, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-2071","authenticated-orcid":false,"given":"Harris A","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Medical Affairs, Immunology and Fibrosis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean E","family":"Connolly","sequence":"additional","affiliation":[{"name":"Global Drug Development, Bristol Myers Squibb , Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G","family":"Conaghan","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds"},{"name":"NIHR Leeds Biomedical Research Centre , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"2022110208001892200_keac073-B1","first-page":"ii14","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2022110208001892200_keac073-B2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2022110208001892200_keac073-B3","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022110208001892200_keac073-B4","first-page":"31","article-title":"Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives","volume":"8","author":"Noisette","year":"2018","journal-title":"Psoriasis (Auckl)"},{"key":"2022110208001892200_keac073-B5","author":"Bristol Myers Squibb","year":"2019"},{"key":"2022110208001892200_keac073-B6","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","article-title":"Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2022110208001892200_keac073-B7","first-page":"2162","article-title":"Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis","volume":"33","author":"Weisman","year":"2006","journal-title":"J Rheumatol"},{"key":"2022110208001892200_keac073-B8","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3899\/jrheum.090352","article-title":"The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA Hands","volume":"36","author":"Ostergaard","year":"2009","journal-title":"J Rheumatol"},{"key":"2022110208001892200_keac073-B9","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.3899\/jrheum.141010","article-title":"Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the hand and foot in a randomized placebo-controlled trial","volume":"42","author":"Glinatsi","year":"2015","journal-title":"J Rheumatol"},{"key":"2022110208001892200_keac073-B10","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3899\/jrheum.110420","article-title":"The OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) is reliable and sensitive to change: results from an OMERACT workshop","volume":"38","author":"Boyesen","year":"2011","journal-title":"J Rheumatol"},{"key":"2022110208001892200_keac073-B11","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.3899\/jrheum.090351","article-title":"Testing an OMERACT MRI scoring system for peripheral psoriatic arthritis in cross-sectional and longitudinal settings","volume":"36","author":"McQueen","year":"2009","journal-title":"J Rheumatol"},{"key":"2022110208001892200_keac073-B12","first-page":"859","article-title":"Developing a magnetic resonance imaging scoring system for peripheral psoriatic arthritis","volume":"34","author":"McQueen","year":"2007","journal-title":"J Rheumatol"},{"key":"2022110208001892200_keac073-B13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jama.1997.03540350075038","article-title":"World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects","volume":"277","year":"1997","journal-title":"JAMA"},{"key":"2022110208001892200_keac073-B14","first-page":"199","article-title":"Guideline: guideline for good clinical practice","volume":"47","year":"2001","journal-title":"J Postgrad Med"},{"key":"2022110208001892200_keac073-B15","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022110208001892200_keac073-B16","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3899\/jrheum.110422","article-title":"Development and preliminary validation of a magnetic resonance imaging joint space narrowing score for use in rheumatoid arthritis: potential adjunct to the OMERACT RA MRI scoring system","volume":"38","author":"Ostergaard","year":"2011","journal-title":"J Rheumatol"},{"key":"2022110208001892200_keac073-B17","author":"Stillfried"},{"key":"2022110208001892200_keac073-B18","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3899\/jrheum.181385","article-title":"Comparing psoriatic arthritis low-field magnetic resonance imaging, ultrasound, and clinical outcomes: data from the TICOPA trial","volume":"47","author":"Helliwell","year":"2020","journal-title":"J Rheumatol"},{"key":"2022110208001892200_keac073-B19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/rheumatology\/key244","article-title":"Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care \u2013 2-year outcomes and predictors","volume":"58","author":"Brahe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2022110208001892200_keac073-B20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jama.2018.21362","article-title":"Effect of magnetic resonance imaging vs conventional treat-to-target strategies on disease activity remission and radiographic progression in rheumatoid arthritis: the IMAGINE-RA randomized clinical trial","volume":"321","author":"Moller-Bisgaard","year":"2019","journal-title":"JAMA"},{"key":"2022110208001892200_keac073-B21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-0035-1564696","article-title":"Recommendations of the ESSR Arthritis Subcommittee for the use of magnetic resonance imaging in musculoskeletal rheumatic diseases","volume":"19","author":"Sudo\u0142-Szopi\u0144ska","year":"2015","journal-title":"Semin Musculoskelet Radiol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac073\/42599368\/keac073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/11\/4305\/46747734\/keac073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/11\/4305\/46747734\/keac073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T08:02:50Z","timestamp":1667376170000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/11\/4305\/6524646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,2,8]]},"published-print":{"date-parts":[[2022,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac073","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,2,8]]}}}